Ustariz-González O, Gordon M, Martínez M, Quiroz-Mercado H

Language: Spanish
References: 7
Page: 272-278
PDF size: 630.73 Kb.

ABSTRACT

Objective: To evaluate security and efficacy of intravitreal bevacizumab in diverse retinal pathologies.
Methods: In a prospective, longitudinal, randomized, experimental study, intravitreal bevacizumab (2.5 mg / 0.1 ml) was injected via pars plana in patients with different retinal pathologies like choroidal neovascular membrane (secondary to age-related macular degeneration and other etiologies), proliferative diabetic retinopathy, diabetic macular edema, and vascular occlusions, among others.
Results: 712 patients were injected, 48% male and 52% female. Patient age ranged from 20 to 98 years. The most part of the patients showed a statistically significant improvement in best corrected visual acuity and macular thickness measured by OCT during 3 months of follow-up.
There were no complications associated to the procedure (intravitreal injection). One patient presented a inflammation reaction in the posterior segment that was treated with intravitreal antibiotics and resolved completely without compromise of visual acuity.
Conclusion: Intravitreal bevacizumab appears to be safe and effective in diverse retinal pathologies. During short-term follow up, different retinal pathologies appeared to respond rapidly to bevacizumab injection, with resolution of increased vascular permeability, macular edema, best corrected visual acuity, and inhibiting neovascularization. The long-term effects remain unknown.

REFERENCES

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25:111-118.

2. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Agerelated macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Survey Ophthalmol 2003; 48(3):257-293.

3. Eugene WM, Adamis A. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40:352-68.

4. Rosenfeld PJ, Moshfegi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-335.

5. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36:336-339.

6. Mordenti J, Cuthbertson RA, Ferrara N y cols. Comparisons of the intraocular tissue distribution pharmacokinetics and safety of 125 I-labeled Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27:536-544.

7. Alvery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26(3):352-354.